BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia

Cancer Genetics

Volumn 209, Issue 5, 2016, Pages 223-228

  He, Rong ^a   Greipp, Patricia T ^a   Rangan, Aruna ^a   Mai, Ming ^a   Chen, Dong ^a   Reichard, Kaaren K ^a   Nelsen, Laura L ^b   Pardanani, Animesh ^a   Hanson, Curtis A ^a   Viswanatha, David S ^a  

^a Mayo Clinic College of Medicine   (United States)

^b Maine General Hospital   (United States)

Author keywords

B lymphoblastic leukemia lymphoma; BCR JAK2 fusion; Eosinophilia; JAK2; Myeloproliferative neoplasm

Indexed keywords

DASATINIB; JANUS KINASE 2; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; JAK2 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BCR JAK2 FUSION GENE; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; EOSINOPHILIA; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; HUMAN; INTERPHASE; JAK2 GENE; LEUKOCYTOSIS; MYELOPHTHISIC ANEMIA; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR REGRESSION; GENE TRANSLOCATION; GENETICS; KARYOTYPE; MULTIPLEX POLYMERASE CHAIN REACTION; MYELOPROLIFERATIVE DISORDER;

ADULT; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; KARYOTYPE; MULTIPLEX POLYMERASE CHAIN REACTION; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCR; TRANSLOCATION, GENETIC;

EID: 84964587156     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2016.03.002     Document Type: Article

References (30)

1. Gotlib J. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. Hematology Am Soc Hematol Educ Program 2013, 2013:529-537.
2. Santos F.P., Verstovsek S. JAK2 inhibitors: what's the true therapeutic potential?. Blood Rev 2011, 25:53-63.
3. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
4. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
5. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
6. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
7. Green M.R., Monti S., Rodig S.J., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
8. Bain B.J., Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?. Br J Haematol 2014, 166:809-817.
9. Griesinger F., Hennig H., Hillmer F., et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005, 44:329-333.
10. Cirmena G., Aliano S., Fugazza G., et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet 2008, 183:105-108.
11. Lane S.W., Fairbairn D.J., McCarthy C., et al. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion. Br J Haematol 2008, 142:503.
12. Angelova S., Spassova S., Toshkov S., et al. Chromosomal translocation t(9;22)(p24;q11) appears to be recurrently associated with myeloid malignancy with aggressive course. Leuk Lymphoma 2011, 52:1809-1810.
13. Impera L., Lonoce A., Fanfulla D.A., et al. Two alternatively spliced 5'BCR/3'JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation. Cancer Genet 2011, 204:512-515.
14. Cuesta-Dominguez A., Ortega M., Ormazabal C., et al. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS ONE 2012, 7:e32451.
15. Elnaggar M.M., Agersborg S., Sahoo T., et al. BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease. Mol Cytogenet 2012, 5:23.
16. Roberts K.G., Morin R.D., Zhang J., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
17. Bellesso M., Santucci R., Dias D.F., et al. Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. Rev Bras Hematol Hemoter 2013, 35:218-219.
18. Xu Y., Yin J., Pan J., et al. A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. Leuk Lymphoma 2013, 54:2322-2324.
19. Chamseddine A.N., Etancelin P., Penther D., et al. Transformation of an unclassified myeloproliferative neoplasm with a rare BCR-JAK2 fusion transcript resulting from the translocation (9;22)(p24;q11). Case Rep Hematol 2015, 2015. 252537.
20. Kantarcioglu B., Kaygusuz-Atagunduz I., Uzay A., et al. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature. Int J Hematol 2015, 102:383-387.
21. Schwaab J., Knut M., Haferlach C., et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 2015, 94:233-238.
22. Tirado C.A., Chen W., Huang L.J., et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. Leuk Res 2010, 34:1674-1676.
23. McClure R., Mai M., Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006, 20:168-171.
24. He R., Mai M., Wood A.J., et al. Sensitive and rapid detection of CALR somatic mutations in myeloproliferative neoplasms using PCR and fragment analysis. J Mol Diagn 2014, 16:1.
25. Patterer V., Schnittger S., Kern W., et al. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol 2013, 92:759-769.
26. McWhirter J.R., Galasso D.L., Wang J.Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993, 13:7587-7595.
27. Cuesta-Dominguez A., Leon-Rico D., Alvarez L., et al. BCR-JAK2 drives a myeloproliferative neoplasm in transplanted mice. J Pathol 2015, 236:219-228.
28. Lierman E., Selleslag D., Smits S., et al. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 2012, 120:1529-1531.
29. Rumi E., Milosevic J.D., Casetti I., et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol 2013, 31:e269-e271.
30. Vainchenker W., Dusa A., Constantinescu S.N. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008, 19:385-393.